Luca Issi
Stock Analyst at RBC Capital
(3.73)
# 799
Out of 5,182 analysts
222
Total ratings
51.06%
Success rate
7.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBIO BridgeBio Pharma | Initiates: Outperform | $100 | $76.18 | +31.27% | 1 | Apr 9, 2026 | |
| QURE uniQure | Upgrades: Outperform | $11 → $35 | $17.45 | +100.57% | 8 | Mar 9, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Sector Perform | $9 → $15 | $15.31 | -2.02% | 8 | Mar 3, 2026 | |
| ASND Ascendis Pharma | Maintains: Outperform | $250 → $275 | $240.29 | +14.45% | 5 | Mar 3, 2026 | |
| ARGX argenx SE | Maintains: Outperform | $925 → $890 | $805.38 | +10.51% | 4 | Feb 27, 2026 | |
| BEAM Beam Therapeutics | Maintains: Sector Perform | $22 → $26 | $30.69 | -15.28% | 8 | Feb 25, 2026 | |
| MRNA Moderna | Maintains: Sector Perform | $25 → $30 | $54.23 | -44.68% | 19 | Feb 17, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $500 → $465 | $308.43 | +50.76% | 29 | Jan 20, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $82 → $95 | $74.78 | +27.04% | 11 | Dec 17, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Outperform | $52 → $80 | $71.05 | +12.60% | 11 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $9 → $27 | $7.34 | +267.85% | 6 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $7 → $10 | $7.53 | +32.80% | 3 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $57 → $28 | $26.29 | +6.50% | 1 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $85 → $8 | $13.49 | -40.70% | 8 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $42 → $50 | $55.54 | -9.97% | 15 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $19 | $9.11 | +108.56% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $30 | $19.21 | +56.17% | 4 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $2.32 | +331.03% | 9 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $21 → $18 | $40.94 | -56.03% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $6.29 | +217.97% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $2 | $0.26 | +676.70% | 6 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $9.32 | +82.40% | 1 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $10.17 | +27.83% | 6 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $35 | $9.76 | +258.61% | 7 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $54.62 | +28.16% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $52.77 | +8.02% | 1 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $3.30 | +21.21% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $77 | $24.10 | +219.50% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $2.25 | +522.22% | 5 | Aug 7, 2024 |
BridgeBio Pharma
Apr 9, 2026
Initiates: Outperform
Price Target: $100
Current: $76.18
Upside: +31.27%
uniQure
Mar 9, 2026
Upgrades: Outperform
Price Target: $11 → $35
Current: $17.45
Upside: +100.57%
Intellia Therapeutics
Mar 3, 2026
Maintains: Sector Perform
Price Target: $9 → $15
Current: $15.31
Upside: -2.02%
Ascendis Pharma
Mar 3, 2026
Maintains: Outperform
Price Target: $250 → $275
Current: $240.29
Upside: +14.45%
argenx SE
Feb 27, 2026
Maintains: Outperform
Price Target: $925 → $890
Current: $805.38
Upside: +10.51%
Beam Therapeutics
Feb 25, 2026
Maintains: Sector Perform
Price Target: $22 → $26
Current: $30.69
Upside: -15.28%
Moderna
Feb 17, 2026
Maintains: Sector Perform
Price Target: $25 → $30
Current: $54.23
Upside: -44.68%
Alnylam Pharmaceuticals
Jan 20, 2026
Maintains: Outperform
Price Target: $500 → $465
Current: $308.43
Upside: +50.76%
Ionis Pharmaceuticals
Dec 17, 2025
Maintains: Outperform
Price Target: $82 → $95
Current: $74.78
Upside: +27.04%
Arrowhead Pharmaceuticals
Dec 11, 2025
Maintains: Outperform
Price Target: $52 → $80
Current: $71.05
Upside: +12.60%
Dec 9, 2025
Upgrades: Outperform
Price Target: $9 → $27
Current: $7.34
Upside: +267.85%
Dec 8, 2025
Maintains: Sector Perform
Price Target: $7 → $10
Current: $7.53
Upside: +32.80%
Nov 20, 2025
Downgrades: Sector Perform
Price Target: $57 → $28
Current: $26.29
Upside: +6.50%
Nov 13, 2025
Downgrades: Sector Perform
Price Target: $85 → $8
Current: $13.49
Upside: -40.70%
Nov 11, 2025
Maintains: Sector Perform
Price Target: $42 → $50
Current: $55.54
Upside: -9.97%
Nov 7, 2025
Maintains: Outperform
Price Target: $17 → $19
Current: $9.11
Upside: +108.56%
Nov 6, 2025
Maintains: Outperform
Price Target: $23 → $30
Current: $19.21
Upside: +56.17%
May 14, 2025
Reiterates: Outperform
Price Target: $10
Current: $2.32
Upside: +331.03%
May 8, 2025
Maintains: Sector Perform
Price Target: $21 → $18
Current: $40.94
Upside: -56.03%
Mar 25, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $6.29
Upside: +217.97%
Mar 18, 2025
Reiterates: Sector Perform
Price Target: $2
Current: $0.26
Upside: +676.70%
Mar 18, 2025
Initiates: Outperform
Price Target: $17
Current: $9.32
Upside: +82.40%
Mar 17, 2025
Maintains: Outperform
Price Target: $11 → $13
Current: $10.17
Upside: +27.83%
Mar 3, 2025
Maintains: Outperform
Price Target: $39 → $35
Current: $9.76
Upside: +258.61%
Feb 20, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $54.62
Upside: +28.16%
Jan 21, 2025
Reiterates: Outperform
Price Target: $57
Current: $52.77
Upside: +8.02%
Dec 13, 2024
Maintains: Sector Perform
Price Target: $5 → $4
Current: $3.30
Upside: +21.21%
Nov 6, 2024
Reiterates: Outperform
Price Target: $77
Current: $24.10
Upside: +219.50%
Aug 7, 2024
Reiterates: Outperform
Price Target: $14
Current: $2.25
Upside: +522.22%